Scientific Advisory Board
Infectious Disease Experts
J. Carl Craft, M.D.
Infectious Disease Chair
Dr. J. Carl Craft was the Chief Executive Officer and Chief Medical Officer of Aquarius Biotechnologies from 2012 until its merger with Matinas BioPharma in 2015. From 2002 to 2007, he was Chief Scientific Officer for Medicines for Malaria Venture (MMV) in Geneva which had the largest ever anti-malarial drug development portfolio with 20 programs of which three were in Phase III clinical trials. Prior to this Dr. Craft worked at Abbott Laboratories as the “Venture Head” of the Anti-Infective Development Group for more than 15 years. Earlier in his career, he was at Tulane University in the Department of Pediatrics Infectious Diseases and Department of Pathology, where he was the Director of Pediatric Closed at the Care Charity Hospital of New Orleans and Director of The Clinical Microbiology Laboratory Tulane Medical Center. He served for two years in the Navy with a rank of Lieutenant Commander and was Chief of Pediatrics at the U.S. Naval Regional Medical Center, Guam, M.I. Dr. Craft serves on the Scientific Advisory Boards for CEMPRA, Drugs for Neglected Disease Institute (DNDi), and ANACOR BMG. He was a Research Fellow in Pediatric Infectious Diseases at The University of Texas, Southwestern Medical School under Drs. John Nelson and George McCracken. He did his residency in Pediatrics at Milwaukee Children's Hospital. He received his M.D. from The George Washington University, Medical School.
Peter G. Pappas, M.D., FACP
Dr. Pappas is the William E. Dismukes Professor of Medicine in the Division of Infectious Diseases in the Department of Medicine at the University of Alabama at Birmingham and the Principal Investigator for the Mycoses Study Group Education and Research Consortium (MSGERC) which performs multicenter trials, creates treatment guidelines for invasive mycoses, and coordinates training in the epidemiology, diagnosis and treatment of invasive mycoses. He is an internationally recognized expert in the treatment and diagnosis of invasive fungal infections with expertise in the development of new therapies for fungal infections and understanding the epidemiology of candidiasis, the endemic mycoses, and cryptococcosis. Over the last 25 years, Dr. Pappas has led numerous clinical trials in candidiasis, cryptococcosis, aspergillosis, sporotrichosis, blastomycosis, and histoplasmosis through his involvement with the National Institute of Allergy and Infectious Disease (NIAID) Bacteriology and Mycology Study Group (BAMSG) and the MSGERC. Dr. Pappas was the principal investigator of a national network of transplant centers, TRANSNET, a collaborative effort of the Centers for Disease Control and Prevention (CDC) and a consortium of industry co-sponsors to provide important epidemiologic and treatment information to transplant recipients who develop proven and probable invasive fungal infections. He is also the co-principal investigator of the Organ Transplant Infection Detection and Prevention Program (OTIP), a collaborative multicenter group funded by the CDC. Dr. Pappas joined the faculty at the University of Alabama in Birmingham School of Medicine in 1988, with a focus on HIV and transplant-associated opportunistic infections, especially the invasive mycoses. Previously, he was on the clinical faculty at the University of North Carolina School of Medicine in Chapel Hill, NC, through its affiliated hospital in Wilmington, North Carolina. Dr. Pappas earned his medical degree in 1978 from the University of Alabama School of Medicine in Birmingham. He completed his residency in internal medicine, chief medical residency, and infectious diseases fellowship at the University of Washington in Seattle.
David S. Perlin, Ph.D.
Dr. Perlin is executive director of the Public Health Research Institute (PHRI) and the Rutgers Regional Biocontainment Laboratory (RBL) of New Jersey Medical School (NJMS), Rutgers Biomedical and Health Sciences. He is also a Professor of Microbiology, Biochemistry and Molecular Genetics at NJMS. Dr. Perlin is an internationally recognized expert and research scientist in infectious diseases who has played a major role in advancing the national research agenda in biodefense and emerging infectious diseases. His primary expertise is in fungal infections, mechanisms of antifungal drug resistance, and rapid diagnosis of opportunistic drug resistant bacterial and fungal pathogens in high-risk patients. Dr. Perlin is the editor-in-chief of the new open access “Journal of Fungi.” He serves on the Board of Directors of the Aaron Diamond AIDS Research Center, and on advisory boards and committees for the Clinical and Laboratory Standards Institute (CLSI), Leading International Fungal Education (LIFE), various pharmaceutical and biotech companies, PinnacleCare and the American Society for Microbiology (ASM). Dr. Perlin also serves on advisory and planning boards for several major international conferences, and he is a member of the Steering Committee for Microbiology, Immunology & Infectious Diseases of the New York Academy of Sciences. He earned a Ph.D. from Cornell University and pursued postdoctoral studies at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry. Dr. Perlin was named a Fellow of the New York Academy of Sciences in 2005, and a Visiting Professor at the University of Manchester, UK in 2009.
Dyslipidemia & Cardiovascular Disease Experts
Christie M. Ballantyne, M.D.
Christie M. Ballantyne, M.D., is currently a Professor of Medicine at Baylor College of Medicine and the Chief of the Sections of Cardiovascular Research and Cardiology. Additionally, Dr. Ballantyne is the Director of The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory and the Director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center as well as the Co-Director of the Lipid Metabolism and Atherosclerosis Clinic at Houston Methodist Hospital.
Dr. Ballantyne has conducted extensive research on the pathophysiology of atherosclerosis, with an emphasis on monocyte activation and adhesion, and led numerous clinical research programs on the prevention of atherosclerotic vascular disease. At The Maria and Alando J. Ballantyne, M.D., Atherosclerosis Clinical Research Laboratory, the core laboratory for the Atherosclerosis Risk in Communities study, he is researching whether novel biomarkers might be useful in identifying individuals at high risk for cardiovascular disease, metabolic syndrome and diabetes. Dr. Ballantyne has received numerous study grants, including an American Heart Association Established Investigator Award, and numerous National Institutes of Health grants.
Dr. Ballantyne earned his degree in medicine from Baylor College of Medicine and performed both his internal medicine residency and postgraduate training at The University of Texas Southwestern Medical School. He completed a cardiology fellowship at Baylor College of Medicine and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor. Dr. Ballantyne is published extensively, speaks nationally and internationally on lipids, atherosclerosis and inflammation, and serves as an editorial director for www.lipidsonline.org. He was recognized by Thomson Reuters as one of The World’s Most Influential Scientific Minds; 2014.
Kevin C. Maki, Ph.D.
Kevin C. Maki, Ph.D. is the Founder and Chief Science Officer of the Midwest Center for Metabolic & Cardiovascular Research, serves as a Clinical Investigator at Great Lakes Clinical Trials and Adjunct Faculty in Biostatistics and Applied Epidemiology at DePaul University in Chicago. He is a certified Clinical Lipid Specialist and a Fellow of the National Lipid Association, The Obesity Society and the American College of Nutrition, as well as a member of the Board of Governors of the Accreditation Council for Clinical Lipidology. Dr. Maki is also a member and spokesperson for the National Lipid Association’s Expert Panel, and a co-author on the paper setting forth the NLA’s patient-centered recommendations for dyslipidemia management (see also: http://www.lipidjournal.com/article/S1933-2874%2814%2900274-8/abstract).
Previously, Dr. Maki was the founder and Chief Scientific Officer at Provident Clinical Research, now Biofortis. Earlier in his career he held positions as the Chief Science Officer and Director of Nutrition and Metabolism Research at the Chicago Center for Clinical Research as well as serving as a Research Scientist at the Edward Hines, Jr. Veterans Affairs Medical Center in Hines in Illinois.
Dr. Maki’s research has been extensively published in more than 200 scientific papers and he has authored or co-authored several books and book chapters, including Practical Lipid Management, Concepts and Controversies. He is a member of the American Heart Association, the American Diabetes Association, the American Society of Nutrition and the Obesity Society. Dr. Maki earned a Ph.D. in Epidemiology from the University of Illinois School of Public Health and a M.S. in Preventive and Rehabilitative Cardiovascular Health from Benedictine University.